Nitric oxide antagonism to anti-glioblastoma photodynamic therapy: Mitigation by inhibitors of nitric oxide generation

26Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

Many studies have shown that low flux nitric oxide (NO) produced by inducible NO synthase (iNOS/NOS2) in various tumors, including glioblastomas, can promote angiogenesis, cell proliferation, and migration/invasion. Minimally invasive, site-specific photodynamic therapy (PDT) is a highly promising anti-glioblastoma modality. Recent research in the authors’ laboratory has revealed that iNOS-derived NO in glioblastoma cells elicits resistance to 5-aminolevulinic acid (ALA)-based PDT, and moreover endows PDT-surviving cells with greater proliferation and migration/invasion aggressiveness. In this contribution, we discuss iNOS/NO antagonism to glioblastoma PDT and how this can be overcome by judicious use of pharmacologic inhibitors of iNOS activity or transcription.

Cite

CITATION STYLE

APA

Fahey, J. M., & Girotti, A. W. (2019, February 1). Nitric oxide antagonism to anti-glioblastoma photodynamic therapy: Mitigation by inhibitors of nitric oxide generation. Cancers. MDPI AG. https://doi.org/10.3390/cancers11020231

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free